About
Once-daily, potent, brain-penetrant, selective c-Abl kinase inhibitor; monoclonal antibody
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyBoston & New England
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
299
By Phase
PHASE1: 4PHASE2: 1
By Status
COMPLETED: 4ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06644326Lead Sponsor
A PK Study of IkT-148009 in Older and Elderly Healthy Subjects
PHASE1Completed
8 participants
Started: Jun 21, 2023 · Completed: Aug 27, 2024
NCT05424276Lead Sponsor
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
PHASE2Active, not recruiting
120 participants
Started: May 15, 2023 · Completed: Jun 30, 2025
NCT06641557Lead Sponsor
A Phase I Dosing Study of IkT-148009.
PHASE1Completed
6 participants
Started: Feb 21, 2023 · Completed: Apr 19, 2023
NCT05623774Lead Sponsor
A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
PHASE1Completed
64 participants
Started: Dec 16, 2022 · Completed: Dec 30, 2024
NCT04350177Lead Sponsor
A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients
PHASE1Completed
101 participants
Started: Feb 16, 2021 · Completed: Jan 30, 2023
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...